Label and Product Information Design to Support Pharmacovigilance in Complex Therapies Pharmacovigilance (PV) is a crucial aspect of ensuring drug safety and efficacy, particularly for complex therapies such as biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products. The regulatory landscape surrounding these therapies is intricate, and compliance with the US FDA regulations is essential for market authorization and post-market compliance. This article provides a comprehensive, step-by-step tutorial on designing effective label and product information that supports robust pharmacovigilance practices. Understanding Pharmacovigilance Requirements Pharmacovigilance involves the science and activities related to the detection, assessment, understanding, and prevention of adverse…

Long-term Follow-Up in Pharmacovigilance for Cell and Gene Therapy The successful implementation of pharmacovigilance (PV) systems is essential for cell and gene therapies, particularly when it comes to understanding their long-term effects. These advanced therapies, classified as Advanced Therapy Medicinal Products (ATMPs), pose unique challenges in terms of monitoring safety and efficacy post-authorization. This article serves as a comprehensive guide for pharma professionals, clinical operations, regulatory affairs, and medical affairs professionals working within the US, UK, and EU. Here, we will detail the specific PV considerations for these therapies, focusing on long-term follow-up (LTFU), traceability, and safety registries. Understanding Pharmacovigilance…

Case studies of safety signals in biosimilars and their regulatory impact Case studies of safety signals in biosimilars and their regulatory impact Introduction to Pharmacovigilance in the Context of Biosimilars Pharmacovigilance is a vital component of drug safety management that entails the process of monitoring and assessing the safety profiles of pharmaceutical products, including biosimilars. By definition, biosimilars are biologic medical products highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency. The dynamic landscape of pharmacovigilance and the regulatory scrutiny surrounding these products necessitate a comprehensive understanding of how…

Risk minimisation for immunogenicity, infusion reactions and complex AEs Risk Minimization for Immunogenicity, Infusion Reactions and Complex Adverse Events Introduction to Pharmacovigilance in Biosimilars, Vaccines, ATMPs, and Specialty Products Pharmacovigilance is a critical aspect of drug development and commercialization, particularly for biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and other specialty products. The primary aim is to ensure drug safety and efficacy throughout the lifecycle of a product. As these therapies often target vulnerable populations, there exists an enhanced need for stringent monitoring and management of risks, notably immunogenicity and complex adverse events (AEs). In the United States, the FDA…

Active Safety Surveillance and Registries for Vaccines and ATMPs Pharmacovigilance plays an essential role in the post-marketing monitoring of vaccines and Advanced Therapy Medicinal Products (ATMPs). The need for robust safety surveillance mechanisms is particularly crucial for these products due to their unique characteristics, such as their complex production processes and potential implications for patient safety. This tutorial aims to provide a comprehensive guide to the regulatory frameworks, strategies for active safety surveillance, and the establishment of safety registries for these products, focusing primarily on the US, while making pertinent comparisons to the EU and UK frameworks. Understanding Pharmacovigilance in…

Methodological challenges in benefit risk for small patient populations Methodological Challenges in Benefit Risk for Small Patient Populations The increasing focus on the assessment of benefit-risk profiles in pharmacovigilance has become particularly important for small patient populations in areas like biosimilars, vaccines, ATMPs (Advanced Therapy Medicinal Products), and specialty products. This article outlines the regulatory expectations and methodological considerations that must be taken into account when evaluating these products, especially given the unique challenges posed by rare diseases and limited patient cohorts. 1. Understanding the Regulatory Framework for Benefit-Risk Assessment Benefit-risk assessment is a fundamental component of drug development and…

Real world data sources to support PV in rare and ultra rare indications Real World Data Sources to Support Pharmacovigilance in Rare and Ultra Rare Indications Pharmacovigilance (PV) plays a critical role in ensuring the safety of medical products, especially in rare and ultra-rare indications. This tutorial provides a comprehensive step-by-step guide for pharmaceutical professionals involved in the development and post-market monitoring of biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products. We will explore various real-world data (RWD) sources, their applications, and how they can be leveraged to enhance PV initiatives. 1. Understanding Pharmacovigilance and Its Importance Pharmacovigilance…

PV agreements and SDEAs specific to biosimilars and ATMP partnerships Understanding Pharmacovigilance Agreements and SDEAs in Biosimilars and ATMP Partnerships As the biotechnology landscape evolves, the importance of effective pharmacovigilance (PV) practices becomes critical, especially in the context of biosimilars and advanced therapy medicinal products (ATMPs). This tutorial aims to guide pharmaceutical professionals through the intricacies of PV agreements and Safety Data Exchange Agreements (SDEAs), shedding light on regulations, best practices, and international standards. 1. Introduction to Pharmacovigilance and Its Significance for Biosimilars and ATMPs Pharmacovigilance is essential for ensuring the safety of pharmaceutical products, encompassing the collection, analysis, monitoring,…

Global alignment of PV strategies for vaccines across US EU and WHO Global alignment of PV strategies for vaccines across US EU and WHO Pharmacovigilance (PV) plays a critical role in ensuring drug safety throughout a product’s life cycle, particularly for vaccines, biosimilars, advanced therapy medicinal products (ATMPs), and specialty products. This regulatory tutorial aims to provide a comprehensive understanding of the pharmacovigilance strategies for vaccines that are harmonized across the United States, European Union, and World Health Organization. By emphasizing key components such as adverse event following immunization (AEFI), traceability, and safety registries, this article will support Pharma professionals,…

Future PV Trends in Cell, Gene, and Personalised Medicines The field of pharmacovigilance (PV) is rapidly evolving, particularly in the context of innovative therapies such as cell, gene, and personalised medicines. This article provides a step-by-step tutorial for professionals in pharmaceuticals, regulatory affairs, and clinical operations to navigate the ongoing changes in PV systems, focusing on biosimilars, vaccines, Advanced Therapy Medicinal Products (ATMPs), and specialty products. The guidance is relevant to stakeholders in the US, UK, and EU, highlighting best practices and regulatory compliance. Understanding Pharmacovigilance in Contemporary Medicine Pharmacovigilance is the science that aims to improve patient safety and…